123 related articles for article (PubMed ID: 16952108)
21. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost.
Nakakura S; Tabuchi H; Kiuchi Y
Optom Vis Sci; 2011 Sep; 88(9):1140-4. PubMed ID: 21666524
[TBL] [Abstract][Full Text] [Related]
22. An evaluation of therapeutic noninferiority of 0.005% latanoprost ophthalmic solution and xalatan in patients with glaucoma or ocular hypertension.
Digiuni M; Manni G; Vetrugno M; Uva M; Milano G; Orzalesi N; Fogagnolo P; Centofanti M; Campos E; Rossetti L
J Glaucoma; 2013 Dec; 22(9):707-12. PubMed ID: 22595934
[TBL] [Abstract][Full Text] [Related]
23. Iris cyst associated with topical administration of latanoprost.
Krohn J; Hove VK
Am J Ophthalmol; 1999 Jan; 127(1):91-3. PubMed ID: 9933009
[TBL] [Abstract][Full Text] [Related]
24. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM;
Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698
[TBL] [Abstract][Full Text] [Related]
25. Audible blink in prostaglandin-associated periorbitopathy.
Fong CS; Rajak SN; Pirbhai A; Selva D
Clin Exp Ophthalmol; 2016 Sep; 44(7):630-631. PubMed ID: 26872687
[No Abstract] [Full Text] [Related]
26. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
Ge J; Li X; Sun X; He X; Zhang H
Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
[TBL] [Abstract][Full Text] [Related]
27. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients.
Costagliola C; Del Prete A; Verolino M; Antinozzi P; Fusco R; Parmeggiani F; Mastropasqua L
Graefes Arch Clin Exp Ophthalmol; 2002 May; 240(5):379-86. PubMed ID: 12073061
[TBL] [Abstract][Full Text] [Related]
28. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
Lewis RA; Levy B; Ramirez N; Kopczynski CC; Usner DW; Novack GD;
Br J Ophthalmol; 2016 Mar; 100(3):339-44. PubMed ID: 26209587
[TBL] [Abstract][Full Text] [Related]
29. The additive effects on intraocular pressure of combining nipradilol 0.25% and latanoprost 0.005% ophthalmic solutions: a prospective, randomized, multicenter study.
Tsuru T; Kitazawa Y; Usui M; Ueno S; Azuma I; Masuda K
Jpn J Ophthalmol; 2008; 52(5):368-373. PubMed ID: 18991037
[TBL] [Abstract][Full Text] [Related]
30. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
[TBL] [Abstract][Full Text] [Related]
31. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
32. A case of cystoid macular edema associated with latanoprost ophthalmic solution.
Tokunaga T; Kashiwagi K; Saito J; Kobayashi K; Kobori Y; Abe K; Tsukahara S
Jpn J Ophthalmol; 2002; 46(6):656-9. PubMed ID: 12543193
[TBL] [Abstract][Full Text] [Related]
33. Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma.
Pillunat LE; Larsson LI;
Br J Ophthalmol; 2003 Dec; 87(12):1492-6. PubMed ID: 14660460
[TBL] [Abstract][Full Text] [Related]
34. Alterations in anterior chamber depth in primary open-angle glaucoma patients during latanoprost therapy.
Cankaya AB; Teberik P; Acaroglu G
Acta Ophthalmol; 2011 May; 89(3):274-7. PubMed ID: 19860780
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
36. Systemic side effects of topical latanoprost.
Rajan MS; Syam P; Liu C
Eye (Lond); 2003 Apr; 17(3):442-4. PubMed ID: 12724721
[No Abstract] [Full Text] [Related]
37. Periocular changes following long-term administration of latanoprost 0.005%.
Ung T; Currie ZI
Ophthalmic Plast Reconstr Surg; 2012; 28(2):e42-4. PubMed ID: 21659917
[TBL] [Abstract][Full Text] [Related]
38. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.
Camras CB; Alm A; Watson P; Stjernschantz J
Ophthalmology; 1996 Nov; 103(11):1916-24. PubMed ID: 8942890
[TBL] [Abstract][Full Text] [Related]
39. Iris cyst secondary to latanoprost mimicking iris melanoma.
Browning DJ; Perkins SL; Lark KK
Am J Ophthalmol; 2003 Mar; 135(3):419-21. PubMed ID: 12614778
[TBL] [Abstract][Full Text] [Related]
40. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
